Phase I, Single and Multiple Dose Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Zemplar Capsule in Subjects with Moderate to Severe Renal Impairment

Study Identifier
M03-633
CT.gov Identifier
M03-633
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Secondary Hyperparathyroidism
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    N/A
    Inclusion and Exclusion Criteria

    Protocol Summary

    To assess the safety, pharmacokinetics, and pharmacodynamics of paricalcitol when administered orally in subjects with moderate to severe renal impairment

    Study Locations

    No locations found.